Implications of genetic polymorphisms in drug transporters for pharmacotherapy
- 1 March 2006
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 234 (1) , 4-33
- https://doi.org/10.1016/j.canlet.2005.06.051
Abstract
No abstract availableKeywords
This publication has 184 references indexed in Scilit:
- Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2)Journal of Biological Chemistry, 2005
- Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping ProbesJNCI Journal of the National Cancer Institute, 2004
- Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific mannerThe American Journal of Cardiology, 2004
- Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy responseAIDS, 2003
- A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depressionThe Pharmacogenomics Journal, 2002
- The genetic basis of variability in drug responsesNature Reviews Drug Discovery, 2002
- Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteinsJournal of Human Genetics, 2001
- Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitutionJournal of Human Genetics, 2001
- P-Glycoprotein gene (MDR1) cDNA from human adrenal: Normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistanceBiochemical and Biophysical Research Communications, 1989
- Chromosomal location of human P-glycoprotein gene sequencesCancer Genetics and Cytogenetics, 1987